当前位置: 首页 > 详情页

Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)

文献详情

编号/登记号:
注册时间:
研究开始时间:
研究结束时间:
项目类型:
本院角色:
多中心研究:
招募状态:
研究疾病/适应症:
研究类型:
研究负责人:
研究单位: [1]Xuan Wu Hospital of Capital Medical University,Beijing,Beijing,China,100053 [2]Beihang University [3]Chinese PLA General Hospital [4]Chongqing Medical University [5]Tianjin Huanhu Hospital [6]The Affiliated Zhongshan Hospital of Dalian University [7]First Hospital of Shijiazhuang City [8]Jilin University

研究目的:
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院